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Abstract: Drug-eluting stents have reduced the risk of in-stent restenosis and have broadened 
the application in percutaneous coronary intervention in coronary artery disease. However, the 
concept of using a permanent metallic endovascular device to restore the patency of a stenotic 
artery has inherited pitfalls, namely the presence of a foreign body within the artery causing 
vascular inflammation, late complications such as restenosis and stent thrombosis, and impeding 
the restoration of the physiologic function of the stented segment. Bioresorbable scaffolds (BRS) 
were introduced to potentially overcome these limitations, as they provide temporary scaffolding 
and then disappear, liberating the treated vessel from its cage. Currently, several BRSs are available, 
undergoing evaluation either in clinical trials or in preclinical settings. The aim of this review is 
to present the new developments in BRS technology, describe the mechanisms involved in the 
resorption process, and discuss the potential future prospects of this innovative therapy.
Keywords: bioresorbable scaffold, drug-eluting stent, biodegradable, design, mechanism, 
coronary artery disease
Introduction
In 1977, Andreas Grüntzig introduced percutaneous transluminal coronary angioplasty, 
opening new horizons in the treatment of coronary artery disease (CAD).1,2 Although 
the potential of this less invasive approach was apparent, the risk of acute occlusion 
and the high incidence of restenosis caused by elastic recoil and neointimal hyperplasia 
limited its application.3–5 Bare metal stents (BMSs) provided a partial solution to these 
problems, by eliminating the risk of acute occlusion and reducing the occurrence of 
restenosis.6–10 With the introduction of drug-eluting stents (DESs), the properties of 
the coated antiproliferative drug prolonged vessel wall healing, limited neointimal 
hyperplasia, and subsequently reduced the prevalence of target lesion revascularization 
(TLR) to less than 10%.11 This resulted in extensive application of DES, especially 
with the use of intravascular ultrasound for the patients with CAD.8,12–16 Conversely, 
delayed endothelization, and the hypersensitivity reaction of the vessel wall to the 
durable polymer, increased the risk of late and very late stent thrombosis (ST).17,18 
Recent advances in DES technology with the use of either a bioresorbable or compatible 
polymer reduced the occurrence of ST but still failed to address other limitations of 
permanent metallic DES, namely the potential risk of neo-atherosclerosis, preclusion 
of surgical revascularization, and the distorted vessel wall physiology caused by the 
presence of a foreign body within the artery.15,19,20
For a number of decades, interventional cardiologists have pursued the possibility 
of a fully bioresorbable scaffold (BRS) that will initially safeguard the patency of 
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the vessel, and then will disappear, thus allowing the artery 
to restore its physiological integrity.21–24 The feasibility 
of this concept was first investigated in the 1990s with 
the Igaki-Tamai® device (Igaki Medical Planning Co, 
Ltd, Kyoto, Japan); this process was however temporarily 
halted with the introduction of metallic DESs. Recently, 
BRS has been heralded as the fourth revolution, rendering 
a novel treatment termed vascular restoration therapy 
(VRT) in interventional cardiology.25 The clear feature of 
VRT is that vessel scaffolding is degraded evanescently, 
and therapeutic advantages may be derived from allowing 
natural vasomotor response in the vessel. In addition, the 
underlying benefits involve decreased or eliminated late ST, 
facilitated re-intervention due to the complete reabsorption 
of the implanted scaffold, improved noninvasive imaging 
of the target site using computed tomography or magnetic 
resonance during post-intervention follow-up, and shortened 
prescription of dual anti-platelet therapy.26 Accordingly, for 
BRS, it is potentially a ideal therapy for CAD, although there 
is still a long way to go to make improvements.
Over the last 5–10 years, considerable efforts were made 
to develop new fully bioresorbable devices. Currently, 
BRS technology has been gradually matured, and there 
are numerous devices available which undergo preclinical 
or clinical testing. In this review article, we present the 
mechanisms of BRS technology, the evolution of individual 
devices, discuss the developments of the currently available 
BRS, and underline their potential value in the treatment 
of CAD.
Design and resorption of the BRSs
For a BRS to be as effective as the currently available DES, 
it should have an increased radial strength that should be 
maintained for at least 3–6 months post device implantation 
and incorporate an antiproliferative drug that would control 
neointimal formation and prevent restenosis. The prolonged 
radial strength can be provided by an appropriate scaffold 
design (eg, increased strut thickness, closed cell design) 
and by the incorporation of a resilient resorbable material 
(polymer or metallic alloy) which would gradually resorb 
so as to prevent late recoil and safeguard the patency of the 
vessel. Although the first generation BRS did not include 
an antiproliferative drug, more recent updated revisions 
incorporate a fully biodegradable polymer that controls the 
release of a drug elution with antiproliferative properties.
The first polymeric (nonbioresorbable polyethylene-
terephthalate) braided mesh stent was designed in 1992.27 
Preclinical evaluation in porcine models demonstrated that 
the developed polymeric stent had comparable safety and 
efficacy to the cotemporary metallic stent. In 1996, van der 
Giessen et al introduced the Wiktor stent, coated with five 
different fully bioresorbable polymers.28 The experimental 
study showed an excessive inflammatory reaction of the 
vessel wall to the device, resulting in increased neointimal 
proliferation and thrombus formation. One year later, 
Lincoff et al reported the first high molecular weight poly-L-
lactic acid (PLLA, 321 kDa) coated stent, that in contrast to the 
low molecular weight (80 kDa) PLLA coated stent, appeared 
to be well tolerated by the vessel wall.29 Yamawaki et al 
were the first to develop a fully BRS, consisting of PLLA 
and a tyrosine kinase inhibitor. Evaluation of the device in 
porcine models demonstrated the safety and efficacy of the 
device and supported its implantation in humans in 1998.30 
These preliminary encouraging results attracted interest and 
drove researchers and industry towards the development of 
several BRSs with different bioresorbable properties and 
composition.19,31–33
Most of the currently available BRSs (eg, Igaki-Tamai 
scaffold, Absorb™ [Abbott Vascular, Santa Clara, CA, USA] 
bioresorbable vascular scaffold [BVS]) are composed of 
PLLA. The catabolism of the PLLA incorporates five stages, 
with the resultant degradation of the polymer to carbon 
dioxide and water (Figure 1).34,35 The first phase includes 
hydration of the polymer, which starts to absorb water from 
the surrounding tissue. The absorbed water catalyzes a 
chain scission at an ester bond, resulting in the degradation 
of the polymer (second stage). Gradually the polymer loses 
its cohesive strength and fragments into segments with 
a lower molecular weight (third stage). Polymer chains 
become progressively hydrophilic through their hydrolysis 
to shorter lengths. The outcomes of the abovementioned 
process are hydrophilic monomers that can be phagocytized 
by macrophages (fourth phase). After phagocytosis, the 
soluble monomer (L-lactate) is catabolized to pyruvate and 
ultimately to carbon dioxide and water through the Krebs 
cycle (fifth stage).36,37
Tyrosine polycarbonate is another polymer used in BRS 
technology (REVA BRS). Its catabolism includes hydrolysis of 
the polymer to carbon dioxide and iodinated-desaminotyrosyl-
tyrosine ethyl esters, which are further hydrolyzed to ethanol 
and iodinated-desaminotyrosyl-tyrosine. Cleavage of the latter 
results in tyrosine molecules and iodinated-desaminotyrosine, 
which are finally catabolized into carbon dioxide and water 
through the Krebs cycle (Figure 2).
Another material used in BRSs to date is magnesium, the 
only metal that has been implemented in BRS technology 
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(absorbable metallic stent [AMS]). A limitation of magne-
sium is its fragility; thus, it has been mixed with several ele-
ments such as zirconium, yttrium, and other rare earth metals 
to provide it with adequate radial strength. An advantage of 
the AMS is the fact that the degradation of the magnesium 
alloy to inorganic salts (Figure 3) triggers only a minor 
inflammatory response, and creates an electronegative charge 
that has been shown to have an anti-thrombogenic effect.38
Currently available BRSs
Currently, there are more than 14 BRSs available (Table 1 
and Figure 4). Most are still either under preclinical 
evaluation or being examined in the clinical setting. Of 
note, two have already acquired certificate Conformité 
Européenne (CE) mark approval and are used in clinical 
practice: the Igaki-Tamai stent for the treatment of peripheral 
vascular disease, and the Absorb BVS for CAD. The 
following sections describe the BRSs that are under clinical 
or preclinical evaluation, and present the evidence from the 
first applications of BRSs in clinical settings or experimental 
studies.
Igaki-Tamai scaffold
The Igaki-Tamai scaffold was the first fully bioresorbable 
stent implanted in humans and was made of PLLA. The first 
revision of scaffold had a helical zigzag design, was mounted 
on a standard angioplasty balloon, and was both thermal 
self-expanding and balloon expandable. Scaffold expansion 
was performed with the use of heated contrast (up to 70°C). 
The device continued expanding after its implantation over a 
20–30 minute period, until it reached its final dimensions.
The f irst-in-man (FIM) study of the Igaki-Tamai 
scaffold included 15 patients treated with 25 scaffolds, 
and showed no major adverse cardiac event (MACE) at 
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Figure 1 Schematic representation of the poly-L-lactic acid bioresorption process. (A) Crystal lamella, interconnected by amorphous chains, absorbs water from the 
surrounding tissue after implantation in the coronary lesion. The amorphous polymer is more susceptible to hydration than the semicrystalline polymer. (B) Schematic 
representation of changes in the radial strength, molecular weight, and mass of the scaffold with time. 
Note: The optical coherence tomography and corresponding molecular images, illustrate the changes in strut appearance and composition of the scaffold with time.
Abbreviations: M, months; P, procedure.
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the first 30 days and only one TLR at 6-month follow-up.39 
Angiographic follow-up performed at day 1 after the device 
implantation revealed a similar percentage diameter stenosis 
and minimal lumen diameter (MLD) compared with the 
post-procedural values (12% ± 8% versus 13% ± 11%; 
2.59 ± 0.35 mm versus 2.58 ± 0.32 mm). At 3 months, the 
MLD decreased (1.88 ± 0.59 mm), with minimal progression 
thereafter at 6 months follow-up (1.84 ± 0.66 mm). Serial 
intravascular ultrasound (IVUS) examinations demonstrated 
a gradual increase in the scaffold cross-sectional area 
(from 7.42 ± 1.51 mm2 post stenting, to 8.18 ± 2.42 mm2 
at 3 months, and 8.13 ± 2.52 mm2 at 6 months; P , 0.1, 
P , 0.1; respectively), whilst the luminal dimensions 
decreased at 3 months, and remained unchanged at 6 months 
(from 7.42 ± 1.51 mm2 after stenting to 5.67 ± 2.42 mm2 at 
3 months, and 5.63 ± 2.70 mm2 at 6 months; P , 0.005, 
P , 0.001; respectively).
Recently, Nishio et al reported the long-term follow-up 
(.10 year) of an observational prospective study which 
enrolled 50 patients (63 lesions) implanted with Igaki-
Tamai scaffolds (84 scaffolds).40,41 The 10-year cumulative 
event-free survival rates of all-cause death, cardiac death, 
and MACE were 87%, 98%, and 50%, respectively, while 
the TLR rate was 16% at 1 year, 18% at 5 years, and 
28% at 10 years. Angiographically, the late lumen loss 
(LLL) was 0.91 ± 0.69 mm at 6 months, which improved 
to 0.67 ± 0.45 mm at 1 year, and was maintained at 3 years 
follow-up (0.59 ± 0.50 mm). IVUS examinations showed 
a reduction in the minimal lumen area at 6 months (from 
5.44 ± 1.89 mm2 after stenting to 3.64 ± 1.68 mm2), 
which started increasing at 1 (4.06 ± 1.61 mm2) and 
3 (5.18 ± 2.09 mm2) years. IVUS echogenicity revealed 
raised hyper-echogenicity of the scaffolded segment 
post device implantation, and then subsequently started 
decreasing to reach the pre-implantation values at 3 years 
follow-up.
Although the short- and long-term follow-up results were 
encouraging, this device failed to progress, mainly due to the 
large guide catheters (8F) required for implantation, and the 
concerns that the heated contrast used for device deployment 
may cause vessel wall injury. The new generation Igaki-Tamai 
scaffold potentially overcomes these pitfalls, as it can be 
implanted through a 6F guide catheter without the need for 
Tyrosine-derived
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Figure 2 The metabolism of tyrosine-polycarbonate scaffold. Initial hydrolysis of the 
tyrosine-polycarbonate produces iodinated-desaminotyrosyl-tyrosine ethyl esters 
(I2DTE), and releases carbon dioxide. 
Notes: I2DTE is hydrolyzed to iodinated-desaminotyrosyl-tyrosine (I2DT) and 
ethanol. Cleavage of I2DT produces tyrosine, and iodinated-desaminotyrosine 
(I2DAT), which enters into the Kreb’s cycle.
Acute 3 months 6 months
Mg + 2H2O → Mg(OH)2 + H2
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Figure 3 Schematic representation of the resorption process in the drug-eluting absorbable magnesium scaffold. 
Notes: The release of the anti-proliferative drug occurs within the first 3 months after device implantation. Hydrolysis of the scaffold affects the radial strength of the scaffold, 
resulting in a gradual degradation of the device into a soft amorphous hydroxyapatite at 9 months follow-up.
Abbreviation: DREAM, drug-eluting absorbable metallic stent.
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a heated contrast agent. The device is currently undergoing 
preclinical evaluation in Germany.
Absorb BVS
The Absorb BVS has a backbone composed by PLLA, and 
is coated with a poly-D,L-lactide (PDLA) polymer that 
contains the anti-proliferative drug everolimus. Histology 
based studies in porcine models have demonstrated that 
scaffold resorption is completed within 3 years post device 
implantation (Figure 5).42
The first generation of Absorb BVS (BVS 1.0) was 
examined in the ABSORB Cohort A Trial (A Clinical 
Evaluation of the Bioresorbable Everolimus Eluting 
Coronary Stent System in the Treatment of Patients with 
de Novo Native Coronary Lesions). The trial aimed to assess 
the feasibility and safety of the scaffold in patients with 
single de novo coronary artery lesion. In this prospective, 
open-label study, 30 patients who had stable, unstable, or 
silent ischemia were enrolled.33 The composite endpoint of 
MACE was cardiac death, myocardial infarction (MI), and 
ischemia-driven TLR. The cumulative estimated incidence 
of MACE was 3.3%, with only one patient having a non-Q 
wave MI and no TLR at 1-year follow-up. No further events 
occurred between 1 and 5 years follow-up.43 Numerous 
invasive imaging modalities were used to assess the efficacy 
of the device, including serial (at baseline, 6 months, and 
2 years) coronary angiography, IVUS, IVUS echogenicity, 
IVUS radiofrequency backscatter analysis, palpography and 
optical coherence tomography (OCT). Angiographically, the 
in-scaffold LLL did not differ between the 6-month and 2-year 
follow-up (0.44 ± 0.35 mm, 0.48 ± 0.28 mm). Intravascular 
ultrasound imaging demonstrated a reduction in the lumen 
area between baseline and follow-up (6.04 ± 1.12 mm2 
at baseline versus 5.19 ± 1.33 mm2 at 6 months and 
5.47 ± 2.11 mm2 at 2 years), which was partially attributed 
to the scaffold shrinkage (6.94 ± 1.70 mm2 immediately post-
procedure and 6.29 ± 1.47 mm2 at the 6 months follow-up).44 
Given this drawback, the scaffold was redesigned, and the 
new revision had a more uniform strut distribution and 
provided increased radial strength to vessel wall.45
The second generation of the Absorb BVS (BVS 
1.1) was tested in the ABSORB Cohort B trial. A total of 
101 patients (102 lesions) treated with 3.0 mm × 18 mm 
Absorb BVS devices were enrolled in this study and divided 
into two groups: Cohort B1 and Cohort B2.46,47 Cohort B1 
had invasive follow-up examinations (quantitative coronary 
angiography [QCA], IVUS, and OCT) at 6 months and 
2 years, while Cohort B2 had the same investigations at 
1 and 3 years. Computed tomographic coronary angiography 
was performed in both groups at 18 months follow-up. The 
rate of MACE in 101 patients was 9.0% (three non-Q-wave 
MI, six ischemia-driven TLR) at 2-year follow-up.48 In the 
Cohort B1 group, QCA analyses demonstrated an LLL of 
0.19 ± 0.18 mm at the 6-month, and 0.27 ± 0.20 mm at 
the 2-year follow-up.49 IVUS examinations performed in 
33 patients demonstrated the minimum lumen area to be 
reduced at 6 months (from 5.45 ± 1.08 mm2 post-procedure to 
5.12 ± 1.01 mm2), with no changes at 2 years (5.13 ± 1.25 mm2), 
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Figure 4 Currently available BRSs. (A) Abbott Vascular BRS 1.0, 1.1; (B) ART BRS 1, 2; (C) REVA Medical BRS I, II; (D) IDEAL scaffold I, II; (E) Igaki-Tamai 
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Abbreviations: BRS, bioresorbable scaffold; DREAMS, drug-eluting absorbable metallic stents.
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whereas the mean lumen area and mean scaffold area 
decreased at 6 months (from 6.53 ± 1.24 mm2 post-procedure 
to 6.36 ± 1.18 mm2 and from 6.53 ± 1.23 mm2 post-procedure 
to 6.42 ± 1.17 mm2, respectively), and then increased at 2 years 
(6.85 ± 1.78 mm2, 7.08 ± 1.73 mm2, respectively). OCT 
examinations showed similar results in 23 patients. In the 
Cohort B2 group, the 1-year follow-up results demonstrated 
the LLL to be 0.27 ± 0.32 mm. The mean scaffold area and 
mean lumen area detected by IVUS were similar between 
post-procedure and 1 year follow-up (6.29 ± 0.92 mm versus 
6.33 ± 0.98 mm and 6.31 ± 0.95 mm versus 6.33 ± 1.17 mm, 
respectively). OCT examinations demonstrated that the mean 
scaffold area did not change, whereas the mean lumen area 
decreased significantly by 23.4% (P , 0.001).
Apart from the ongoing ABSORB Cohort B trial, three 
other clinical trials are underway: the ABSORB Physiology, 
the ABSORB II, and the ABSORB EXTEND. The ABSORB 
Physiology study aims to estimate the short- and long-
term effects of an Absorb BVS and a Xience V® (Abbott 
Vascular, Santa Clara, USA) stent on the physiology of the 
vessel wall, and will include the following metrics: vascular 
compliance, distensibility, endothelial responsiveness, 
and shear stress distribution. The ABSORB II study is the 
first randomized trial designed to compare the safety and 
efficacy of the Absorb BVS and the analogous metallic 
stent (Xience prime, Abbott Laboratories) in 500 patients 
with de novo coronary artery disease. Finally, the ABSORB 
EXTEND registry aims to recruit 1000 patients with de 
novo single or two-vessel disease and test the efficacy of 
the device in clinical settings. In contrast to the previous 
studies, this single-arm study will include long lesions 
and small caliber vessels with a reference vessel diameter 
of 2.0–2.5 mm.50
Magnesium metallic stents (AMSs)
An AMS (Biotronik, Berlin, Germany) is a tubular, slotted 
balloon-expandable stent sculptured by laser from a tube of 
magnesium alloy. The device has similar mechanical strength 
to other metallic stents. In the first generation AMS 1.0, the 
resorption process was almost completed at 2 months after 
Figure 5 OCT, and corresponding histology, images at 28 days and 2, 3, and 4 years follow-up after Absorb BVS implantation.32 At 28 days, the struts appeared as 
preserved black boxes in OCT covered by neointimal tissue (A); Alcian Blue Staining at 28 days confirms the structural integrity of the polymeric struts which were 
completely covered by neointima (Ai); at 2-year follow-up, the struts conformed to the “preserved box” in OCT (B); these “preserved boxes” structures had discrete 
borders and were stained positively by Alcian Blue, indicating that they were composed of acid mucopolysaccharides (proteoglycans) (Bi); at 3-year follow-up, the “preserved 
boxes” were only visible at 8 and 9 o’clock in OCT, (C); at the same time point of the histological images, the trichrome staining demonstrated the presence of connective 
tissue in the strut footprint (Ci); the region of the preexisting strut was integrated only in a minority of cells which were observed positively with smooth muscle actin 
through the immunohistochemical staining (Cii); and proteoglycan matrix detected by the Alcian Blue staining (Ciii); at 4-year follow-up, the struts are no longer discernible 
by OCT (D); the locations in the arterial wall suggestive of prior strut location were circumscribed with connective tissue using the trichrome staining (Di); there was a 
paucity of cells within the connective tissue which was stained positively with smooth muscle actin (Dii); while the Movat pentachrome staining also confirmed that the strut 
locations were minimally discernible (Diii). Reprinted with permission Onuma Y, Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 
1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human 
optical coherence tomography images in the ABSORB trial. Circulation. 2010;122(22):2288–2300. © Wolters Kluwer 2010.
Abbreviations: OCT, optical coherence tomography; BVS, bioresorbable vascular scaffold.
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implantation, resulting in late vessel recoil. To address this 
limitation, the scaffold was redesigned, and in the latest 
revision (drug-eluting AMS, DREAM 2.0) the process was 
prolonged to 6 months.
The efficacy of the first generation AMS was validated 
in the PROGRESS-AMS (Clinical Performance and 
Angiographic Results of Coronary Stenting) study, which 
was a nonrandomized, multicenter trial that included 63 
patients who had de novo lesions with lengths of 10–15 mm 
and reference diameters of 3.0–3.5 mm.51 During a follow-up 
period of 4 months, there was a 23.8% clinically driven TLR 
incidence, associated with a high LLL (1.08 ± 0.49 mm).31 
From 4 to 12 months, only one further patient sustained 
TLR, resulting in a cumulative incidence of MACE at 
12 months of 26.7%. These results were attributed to 
neointimal proliferation and vessel recoil caused by the 
premature reduction in the radial strength of the implanted 
devices. To overcome these limitations, the company added 
the antiproliferative drug paclitaxel, and changed the design 
of the scaffold and the composition of the magnesium alloy, 
thus providing the device with increased strength, and a 
prolongation of its resorption process. The efficacy of the 
new revision DREAMS (drug-eluting absorbable metallic 
stents) 1.0 was evaluated in the BIOSOLVE-1 trial. In 
this prospective multicenter FIM trial, 46 patients with a 
single de novo coronary artery lesion were implanted with 
47 scaffolds.52 At 1-year follow-up, the MACE rate was 7% 
(two TLR and one MI), whereas the LLL, although improved, 
remained high (0.52 ± 0.39 mm).
The second generation DREAMS (DREAMS 2.0) scaffold 
incorporates sirolimus elution instead of paclitaxel. Preclinical 
evaluation of the device revealed reduced inflammation, and 
a higher endothelization rate compared with the previous 
revision. Further evaluation is however needed to confirm 
these positive results in clinical settings and to examine its 
safety and efficacy in the treatment of CAD.
REVA scaffold
The REVA scaffold (Reva Medical Inc, San Diego, CA, USA) 
is made by a tyrosine-derived polycarbonate polymer. The 
first revision of the REVA scaffold had a distinctive slide-
and-lock mechanism that provided for a robust radial strength 
to the device post implantation.53
The long-term (55 months) performance of the first 
generation REVA scaffold was reported in a healthy porcine 
model recently. In this report, serial IVUS examinations 
showed a gradual increase in the lumen area during 
follow-up (lumen area change, defined as % lumen increase 
post-implantation: 86% ± 23% at 5 days, 94% ± 10% at 
12 months, and 114% ± 23% at 55 months).54 The clinical 
performance of this first generation device was evaluated 
in the RESORB (The REVA endovascular study of a 
bioresorbable coronary stent) study. Twenty-five patients 
with single de novo lesions were implanted with the studied 
scaffolds. Angiographically, the MLD increased from 
0.88 ± 0.39 mm to 2.76 ± 0.36 mm after device deployment, 
resulting in an acute gain similar to that reported with the 
current metallic stents. However, a high TLR rate was noted 
between 4- and 6-month follow-up, which was predominantly 
attributed to focal mechanical failures leading to the 
redesign of scaffold.55 The ReZolve is the second revision 
of REVA scaffold, has a spiral slide-and-lock mechanism, 
and contains the antiproliferative drug sirolimus. The new 
generation scaffold is currently undergoing evaluation in 
the RESTORE (ReZolve sirolimus-eluting bioresorbable 
coronary scaffold) clinical trial, which aims to investigate 
its safety and efficacy in 50 patients. The primary endpoints 
of this study are ischemic-driven TLR at 6 months, and 
quantitative measurements (QCA and IVUS) at 12 months. 
Concomitantly, a pivotal trial which aims to apply for the CE 
mark approval has been initiated.
DESolve™ bioresorbable coronary 
scaffold
The DESolve BRS (Elixir Medical Corporation, Sunnyvale, 
CA, USA) is composed of a PLLA polymer and contains two 
novel antiproliferative drugs (Novolimus and Myolimus). 
The radial strength of the device is comparable with the 
Elixir’s BMS, and its resorption process takes approximately 
2–3 years.56
The safety and efficacy of the DESolve scaffold was 
evaluated in a prospective, multicenter FIM trial, which 
included patients with a single de novo coronary artery 
lesion, with a reference vessel diameter of 3.0 mm and lesion 
length , 10 mm. At present, 16 patients have been enrolled.57 
Clinically indicated TVR was reported in one patient who 
underwent emergency coronary artery bypass graft for a 
procedurally related spiral dissection at 30 days follow-up. 
One clinically indicated TLR occurred between 30 days and 
180 days follow-up, while no cardiac death, MI, and ST have 
been reported at 6-month follow-up. QCA revealed an LLL 
of 0.19 ± 0.19 mm at 6-month follow-up. IVUS examination 
showed a minor reduction in the lumen area and an increase 
in the scaffold area at 6 months (5.35 ± 0.78 mm2 versus 
5.10 ± 0.78 mm2 at 6 months and 5.35 ± 0.78 mm2 versus 
5.61 ± 0.81 mm2, respectively). OCT examination in ten patients 
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showed that 98.68% ± 2.44% of the struts was fully covered 
at 6 months follow-up, and a mean neointimal hyperplasia 
area of 0.71 ± 0.36 mm2. Based on this initial promising data, 
the DeSolve NX study has recently commenced, and aims to 
evaluate the safety and efficacy of the device. The study is 
expected to include 120 patients with single de novo coronary 
artery lesions. In-scaffold LLL at 6-month follow-up is the 
principal endpoint. In addition, the DeSolve NX II pivotal trial 
has been designed to evaluate the effectiveness of the device in 
a broader number of patients to provide sufficient evidence for 
CE mark approval and is expected to start in due course.58
Ideal™ BioStent
The Ideal BioStent (Xenogenics Corp, Canton, MA, USA) is 
a fully bioresorbable balloon expandable scaffold. The device 
consists of a core backbone and a top coat. The backbone is 
synthesized from polylactide anhydride, and a trimer of two 
salicylic acid molecules joined by a sebacic acid, while the top 
coat part is comprised of salicylate and the antiproliferative 
drug sirolimus. Preclinical studies have demonstrated the 
potential anti-inflammatory and antiplatelet properties of 
salicylate, which appears to reduce restenosis and promote 
vessel healing during the polymer’s degradation.59,60
The first generation scaffold (BTI) was examined in 
the “WHISPER” study. Eleven patients were included in 
this prospective FIM trial that evaluated the safety and 
efficacy of the scaffold.61 Coronary angiography and IVUS, 
performed post-procedurally and at follow-up, revealed the 
absence of scaffold recoil. However, IVUS and OCT showed 
increased neointimal formation, which was attributed to the 
inadequate drug dose and fast drug elution. In view of the 
high restenosis rate, the device was redesigned. The revised 
device (Ideal BioStent) has a higher drug dose, slower drug 
release kinetics, and an easy to use peel-away sheath. The new 
generation Ideal scaffold is currently undergoing preclinical 
evaluation, with a plan for the initiation of clinical trials in 
the near future.
ART BRS
The ART BRS (Arterial Remodeling Technologies, Noisy 
le Roi, France), is a fully BRS made by a PLLA amorphous 
polymer, without any antiproliferative drug. The new revision 
device was named ART18Z. The resorption process of the 
scaffold starts at 3 months and is expected to be completed 
between 18 and 24 months. To date, more than 250 devices 
have been implanted in porcine models, and no MACE 
(defined as a composite of thrombosis, death, and MI) 
have been reported.62 QCA analyses have shown that the 
ART18Z scaffold has similar acute recoil and LLL, at 6 and 
9 months, in comparison to the Multilink Vision stent (Abbott 
Vascular, Santa Clara, CA, USA). At 9 months follow-up, 
the LLL decreased in the ART18Z group, a finding that was 
attributed to late lumen enlargement and positive arterial 
remodeling.63 The performance of the ART18Z scaffold is 
currently being investigated in the clinical setting, in the 
“ARTDIVA” (Arterial Remodeling Transient DIsmantling 
Vascular Angioplasty) FIM trial, which commenced at five 
clinical centers in the third quarter of the year 2012.
Amaranth bioresorbable stent
The Amaranth BRS (Amaranth Medical Inc, Mountain 
View, CA, USA) is made of PLLA, with proprietary tube 
fabrication. The structural integrity of the Amaranth scaffold 
lasts 3–6 months, and the resorption process of scaffold 
requires roughly 1–2 years. Preliminary experimental studies 
have shown that the scaffold has a high radial strength, 
prolonged mechanical stability, and exhibits minimal recoil.64 
A recent report evaluated the performance of the scaffold in 
porcine models compared with the Liberte BMS (Boston 
Scientific, Natick, MA, USA). A similar LLL was reported 
at 28- and 90-day follow-up. However, thereafter the LLL 
started to decrease in the Amaranth group, whereas this 
increased in the Liberte BMS group, from 90-day to 180-day 
follow-up. OCT examination at 90 days follow-up revealed 
a lower neointimal thickness in the Amaranth scaffold 
compared with the Liberte group. The company is currently 
designing the FIM study that will recruit 30 patients in order 
to evaluate the safety and efficacy of the Amaranth scaffold, 
with a plan for the conduction of a prospective, multicenter 
CE mark trial.
Xinsorb BRS
The Xinsorb BRS (Huaan Biotechnology Co, Ltd, Hangzhou, 
Zhejiang, People’s Republic of China) is a fully bioresorbable 
sirolimus-loaded scaffold, consisting of poly(aspartic acid-co-
lactide), poly(ε-caprolactone), and polyglycolide. The device 
is balloon expandable, and has radiopaque markers to facilitate 
its deployment. The available scaffold size ranges from 2.75 
to 4.0 mm in diameter, and from 12 to 28 mm in length.
A recent experimental study evaluated the feasibility 
and efficacy of the Xinsorb scaffold compared with the 
Excel DES (JW Medical Co, Shandong, People’s Republic 
of China).65 Sixteen Xinsorb scaffolds and 16 Excel stents 
were implanted in the coronary arteries of porcine models.66 
Histomorphometry demonstrated a lower percentage 
diameter restenosis in the Xinsorb scaffold compared with 
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the Excel DES (at 30-day follow-up, 18.6% ± 5.2% versus 
21.4% ± 7.2%, P . 0.05; at 90-day follow-up, 24.5% ± 4.7% 
versus 27.7% ± 5.6%, P . 0.05, respectively). Although 
these preliminary results are encouraging, further extensive 
preclinical studies are necessary to investigate the safety and 
efficacy of the scaffold. The company is expected to organize 
an FIM trial in 2013.
Acute BRS
The Acute BRS (OrbusNeich, Fort Lauderdale, FL, USA) 
is a tube-shaped lockable and balloon-expandable BRS. The 
device consists of three polymeric materials (poly-L-lactide-
co-ε-caprolactone, PDLA, and PLLA) and incorporates a 
partitioned coating technology, which allows for the scaffold 
to be covered by abluminal sirolimus and luminal endothelial 
progenitor cell capture (+CD34) antibodies. Preliminary 
preclinical evaluation demonstrated an optimal device 
implantation without evidence of fracture.67 Updated data 
are expected to be presented in the EuroPCR Focus Group 
2013.
MeRes™ BRS
MeRes BRS (Meril Life Sciences, Vapi, Gujarat, India) is 
a merilimus eluting bioresorbable coronary scaffold. The 
device is comprised of a new PLA formulation and has a 
hybrid scaffold geometry structure, which gives the scaffold 
a high radial strength. The performance of the device was 
examined in an experimental animal study. Initial results 
showed that the elution of the coated drug merilimus lasts 
more than 30 days, with no evidence of inflammatory reaction 
during the polymer’s biodegradation.64
FADES BRS
The FADES scaffold (Zorion Medical, Indianapolis, IN, 
USA) is a fully bioresorbable drug-eluting scaffold. The 
polymer of the scaffold involves a hybrid material of 
magnesium alloy that includes rare earth elements and PLGA. 
Preclinical studies showed that the device was completely 
absorbed with little to no inflammatory tissue response within 
90 days.64 Further preclinical evaluations are needed before 
the conduction of the FIM study.
Other BRSs
Three other devices are under development: the Avatar BRS 
(S3V Vascular Technologies, Bangalore, Karnataka, India), 
the Sahajanand BRS (Sahajanand Medical Technologies, 
Surat, Gujarat, India), and Stanza™ BRS (480 Biomedical, 
Boston, Massachusetts, USA). All these three BRSs are 
in their infancy, and preclinical and clinical evaluation is 
pending.64
Conclusion
BRSs introduce a unique potential in the treatment of coronary 
lesions, as they provide temporary vessel scaffolding, and 
then they disappear, thereby allowing for the restoration of 
the vessel wall physiology and vasomotion. Initial preclinical 
and clinical results appear promising. However, it should be 
mentioned that our clinical data are limited to simple lesions 
and there is no evidence in the context of randomized control 
trials that would allow direct comparison of the efficacy of 
the BRS with the effectiveness of the new generation DES. 
Furthermore, BRS technology has significant limitations such 
as the bulky nature of the devices, the fact that they cannot be 
implemented to treat bifurcation lesions requiring a two stent 
strategy, the concerns about an increased risk of restenosis 
in case of overlapping, and their limited extensibility and 
the risk of scaffold fracture that limit their applications in 
the current clinical practice. Therefore further development 
is necessary so as to reduce the thickness of the struts and 
increase the extensibility of the devices so as to overcome the 
current pitfalls of BRS technology and become the workhorse 
device for the treatment of CAD.
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